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2664Hemodynamics of
Mechanical Circulatory SupportABSTRACTAn increasing number of devices can provide mechanical circulatory support (MCS) to patients with acute hemodynamic
compromise and chronic end-stage heart failure. These devices work by different pumping mechanisms, have various
ﬂow capacities, are inserted by different techniques, and have different sites from which blood is withdrawn and returned
to the body. These factors result in different primary hemodynamic effects and secondary responses of the body.
However, these are not generally taken into account when choosing a device for a particular patient or while
managing a patient undergoing MCS. In this review, we discuss fundamental principles of cardiac, vascular, and pump
mechanics and illustrate how they provide a broad foundation for understanding the complex interactions between
the heart, vasculature, and device, and how they may help guide future research to improve patient outcomes.
(J Am Coll Cardiol 2015;66:2663–74) © 2015 by the American College of Cardiology Foundation.F or patients with advanced heart failure, thereare an increasing number of therapies, espe-cially in the form of mechanical circulatory
support (MCS). There are several classes of MCS de-
vices, distinguished by hemodynamic characteristics
of the pump, the sites from which blood is withdrawn
and returned, the size of catheters and/or cannulas
used, whether the insertion technique is percuta-
neous or surgical, and whether or not a gas exchange
unit is used. Some devices are for short-term
use, whereas others can be used for the duration of
a patient’s life. These characteristics contribute to
determining the ease of deployment, ease of patient
management while on the device, and overall safety
proﬁle, as reviewed recently in detail (1). To varying
degrees, all available devices improve cardiac output
and blood pressure (2–5), but their speciﬁc features
result in different overall hemodynamic effects. The
implications of these differences are only partially
understood (6) and have not yet been researched in
clinical trials.
Right heart catheterization with a pulmonary
artery catheter (PAC) is the cornerstone of a standard
clinical hemodynamic evaluation of patients under-
going MCS. However, widespread routine use of PAC
has declined over the past decade and there is no
consensus on systematic use of PAC data (7). As a
result, important differences in hemodynamic effects
of different forms of MCS may have gone unrecog-
nized. A full understanding from advanced hemo-
dynamic principles of the mechanisms of such
differences has the potential to impact clinical prac-
tice and outcomes.
This review aims to provide a concise overview of
advanced hemodynamic principles, including thebasics of ventricular mechanics, ventricular-vascular
coupling, and myocardial energetics (see [8–10] for
detailed descriptions). We will then review how these
principles can be applied to better understand the
hemodynamic effects of MCS.
FUNDAMENTALS OF
LEFT VENTRICULAR MECHANICS
Events occurring during a single cardiac cycle are
depicted by ventricular pressure–volume loops (PVLs)
(Figure 1A). Under normal conditions, the PVL is
roughly trapezoidal, with a rounded top. The 4 sides
of the loop denote the 4 phases of the cardiac cycle:
1) isovolumic contraction; 2) ejection; 3) isovolumic
relaxation; and 4) ﬁlling. The loop falls within the
boundaries of the end-systolic pressure–volume
relationship (ESPVR) and the end-diastolic pressure–
volume relationship (EDPVR). The ESPVR is reason-
ably linear, with slope Ees (end-systolic elastance)
and volume–axis intercept Vo. The EDPVR is
nonlinear and described by simple equations, such as:
P ¼ b(ea[V-Vo] – 1) or P ¼ bVa. ESPVR, and EDPVR shifts
occur with changes in ventricular contractility and
diastolic properties (remodeling).
The actual position and shape of the loop depend
on ventricular pre-load and afterload. At the organ
level, pre-load can be deﬁned as either end-diastolic
pressure (EDP) or the end-diastolic volume (EDV),
which relate to average sarcomere stretch throughout
the myocardium. Afterload is determined by the he-
modynamic properties of the vascular system against
which the ventricle contracts and is most generally
characterized by its impedance spectrum (the
frequency-dependent ratio and phase shift between
AB BR E V I A T I O N S
AND ACRONYM S
CVP = central venous pressure
Ea = effective arterial
elastance
ECMO = extracorporeal
membrane oxygenation
EDP = end-diastolic pressure
EDPVR = end-diastolic
pressure–volume relationship
EDV = end-diastolic volume
Ees = end-systolic elastance
ESPVR = end-systolic
pressure–volume relationship
LA = left atrial/atrium
LV = left ventricle/ventricular
LVAD = left ventricular assist
device
MAP = mean arterial pressure
MCS = mechanical circulatory
support
MVO2 = myocardial oxygen
consumption
PAC = pulmonary artery
catheter
PCWP = pulmonary capillary
wedge pressure
Pes = ventricular end-systolic
pressure
PVA = pressure–volume area
RA = right atrial/atrium
RPM = rotations per minute
RV = right ventricle/ventricular
SV = stroke volume
TPR = total peripheral
resistance
Vo = volume–axis intercept
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2665pressure and ﬂow, as determined by Fourier anal-
ysis). Afterload is more simply indexed by total pe-
ripheral resistance (TPR), the ratio between mean
pressure and ﬂow. Afterload can also be depicted on
the pressure–volume plane by the “effective arterial
elastance” (Ea) line (Figure 1A) (11). The slope of the
Ea line is approximately equal to TPR/T, where TPR is
in units of mm Hg , s/ml and T is the duration of the
heartbeat in seconds. The Ea line starts on the volume
axis at the EDV and intersects the ESPVR at the ven-
tricular end-systolic pressure-volume point of the
PVL. This allows approximation of stroke volume (SV)
(the width of the loop) and ventricular end-systolic
pressure (Pes) (the height of the loop). Pes is closely
related to mean arterial pressure (MAP): MAP
z 0.9,Pes. When TPR, heart rate, or pre-load volume
changes, the Ea line rotates and/or shifts so that its
intersection with the ESPVR occurs at a different
point (Figure 1B). This construct can be used to un-
derstand ventricular–vascular coupling, which is the
science of describing how SV, MAP, and other key
cardiovascular parameters are determined by pre-
load, afterload, and contractility (Figure 1B). Specif-
ically, SV can be estimated according to: SVz (EDV 
Vo)/(1 þ Ea/Ees). Cardiac output is obtained by
multiplying SV by heart rate, and ejection fraction is
obtained by dividing SV by EDV. Similarly, MAP can
be estimated by: MAPz0.9,(EDVVo)/(1/Eesþ 1/Ea).
The ESPVR shifts with changes in ventricular
contractility (Figure 1C) (8,12). Increases and de-
creases in contractility are associated with leftward
and rightward shifts of the ESPVR, respectively,
which are generally manifested as changes in Ees. In
reality, Vo can also shift with changes in contractility.
It is therefore necessary to account for changes of
both Ees and Vo when using ESPVR to index
contractility. This can be achieved through use of an
index that integrates changes in both Ees and Vo,
such as V120, the volume at which the ESPVR reaches
120 mm Hg: V120 ¼ 120/Ees þ Vo. Higher values of
V120 are associated with decreased contractility and
vice versa.
The EDPVR is nonlinear and deﬁnes the passive
diastolic properties of the ventricle (Figure 2A). This
nonlinearity introduces complexity when indexing
diastolic properties, speciﬁcally diastolic stiffness.
Stiffness is the change in pressure for a given change
in volume (dP/dV). Accordingly, diastolic stiffness
varies with ﬁlling pressure, increasing as EDP
increases, even in normal hearts. Some reports
incorrectly quantify stiffness by the ratio of EDP to
EDV (P/V), which also varies with ﬁlling pressure
(Figure 2A). From an engineering perspective, dia-
stolic material properties of the heart can be moreappropriately indexed by its dimensionless
stiffness constant, deﬁned as (dP/dV)/(P/V)
(8). For the case when the EDPVR is ﬁt to the
equation P ¼ bVa, it can be shown that a is the
stiffness constant. Because it requires
measuring EDP and EDV over a range of vol-
umes, quantiﬁcation of the stiffness constant
can be difﬁcult in practice, especially when
EDP is low and the nonlinear portion is not
readily apparent.
Another index of diastolic properties is
ventricular capacitance (Figure 2B), the vol-
ume at a speciﬁed ﬁlling pressure. Capaci-
tance indexes the degree to which the EDPVR
is either dilated (as with ventricular remod-
eling in chronic heart failure with reduced
ejection fraction) or smaller than appropriate
(as occurs in hypertrophic cardiomyopathy
and other forms of diastolic heart failure). We
and others have used V30, the volume at an
EDP of 30 mm Hg, as the index of ventricular
capacitance.
In addition to providing a platform for
explaining ventricular mechanics, the pres-
sure–volume diagram also provides a plat-
form for understanding the determinants of
myocardial oxygen consumption (MVO2)
(Figure 3A) (13). MVO2 is linearly related to
ventricular pressure–volume area (PVA),
which is the sum of the external stroke work
(the area inside the PVL) and the potential
energy. Potential energy is the area bounded
by the ESPVR, the EDPVR, and the diastolic
portion of the PVL, and represents the resid-
ual energy stored in the myoﬁlaments at the
end of systole that was not converted to
external work.APPLICATION TO MCS
Current modes of left ventricular (LV) MCS can be
characterized by 1 of 3 different circuit conﬁgurations
(Central Illustration): 1) pumping from the right atrium
(RA) or central vein to a systemic artery; 2) pumping
from the left atrium (LA) to a systemic artery; or 3)
pumping from the LV to a systemic artery (generally
the aorta). Peak ﬂow rates achievable by different
systems range from approximately 2.5 to 7.0 l/min.
Flow rates and circuit conﬁgurations both have a
major impact on their overall cardiac and systemic
effects. Many other factors also affect the response to
MCS, including: 1) the cardiovascular substrate (i.e.,
whether the patient has a prior history of chronic
heart failure with a dilated, remodeled LV and/or
FIGURE 1 Overview of PVLs and Relations
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(A) Normal pressure–volume loop (PVL), is bounded by the end-systolic pressure–volume relationship (ESPVR) and end-diastolic pressure–volume rela-
tionship (EDPVR). ESPVR is approximately linear with slope end-systolic elastance (Ees) and volume–axis intercept (Vo). Effective arterial elastance (Ea) is
the slope of the line extending from the end-diastolic volume (EDV) point on the volume axis through the end-systolic pressure–volume point of the loop.
(B) Slope of the Ea line depends on total peripheral resistance (TPR) and heart rate (HR), and its position depends on EDV. (C) The ESPVR shifts with changes
in ventricular contractility, which can be a combination of changes in Ees and Vo. Changes in contractility can be indexed by V120, the volume at which the
ESPVR intersects 120 mm Hg. ESV ¼ end-systolic volume; LV ¼ left ventricular.
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2666right ventricle [RV], or whether it is a ﬁrst event,
with previously normal heart structure); 2) the de-
gree of acute LV recovery following initiation of
MCS (e.g., potentially recoverable in some forms of
acute coronary syndrome, but less likely recover-
able with idiopathic cardiomyopathy); 3) right-sided
factors, such as RV systolic and diastolic function
and pulmonary vascular resistance; 4) the degree to
which baroreﬂexes are intact and can modulate
vascular and ventricular properties; 5) concomitant
medications; and 6) metabolic factors, such as
pH and pO2, which, if corrected, could result inFIGURE 2 Characteristics of the EDPVR
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volume at a speciﬁed pressure such as V30, the volume at 30 mm Hg. Aimproved ventricular and vascular function. Finally,
the characteristics of the pump (e.g., pulsatile,
axial, or centrifugal ﬂow) can also have an impact
on several aspects of the hemodynamic responses
to MCS (14).
It is therefore important to understand and
distinguish between the primary hemodynamic
effects of a device (i.e., the expected effects on
pressures and ﬂow in the absence of any change in
native heart or vascular properties) and the net
hemodynamic effects observed after accounting for
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bbreviations as in Figure 1.
FIGURE 3 Myocardial Energetics Assessed on the Pressure–Volume Diagram
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(A) Pressure–volume area (PVA) is the sum of the stroke work (SW) and potential energy (PE). (B) Myocardial oxygen consumption (MVO2) is
linearly correlated with PVA and is divided into 3 major components, as indicated in the ﬁgure. LV ¼ left ventricular.
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2667following initiation of MCS. Both components of
device effects will be discussed later.
Finally, use of the theories of ventricular me-
chanics detailed earlier within the context of a
comprehensive cardiovascular simulation (9,10)
facilitates illustration and comparison of the hemo-
dynamic effects of different forms of MCS. The
simulation we used has been detailed, can be used to
understand the physiology of MCS, and has been
validated to a certain degree pre-clinically (15). Other
aspects of validation and limitations of the simulation
have also been detailed previously (15–17). Note that
the response of a given patient to MCS must account
for baseline pre-load, afterload LV contractility, and
the ﬂow rate of the MCS pump. For simplicity, sub-
sequent comparisons keep these factors constant.
Importantly, the basic principles to be discussed
apply across a wide range of conditions.
RA-TO-ARTERIAL CIRCULATORY SUPPORT. Extra-
corporeal venoarterial membrane oxygenation
(ECMO), also referred to as extracorporeal life sup-
port, utilizes a pump with the capacity to assume
responsibility for the entire cardiac output and a gas
exchange unit for normalizing pCO2, pO2, and pH.
However, strictly on a hemodynamic basis, the use of
this circuit conﬁguration can cause signiﬁcant in-
creases in LV pre-load and, in some cases, pulmonary
edema. This is illustrated in Figure 4A, which depicts
PVLs in a case of cardiogenic shock due to profound,
irreversible LV dysfunction. Baseline cardiogenic
shock conditions (PVL in black) have a high LV EDP,
low pressure generation, low SV, and low ejection
fraction. As ECMO ﬂow is initiated and increased
stepwise from 1.5 to 3.0 to 4.5 l/min, the primaryhemodynamic effect is increased LV afterload pres-
sure and effective Ea. If TPR and LV contractility are
ﬁxed, the only way for the LV to overcome the
increased afterload is via the Starling mechanism, and
blood accumulates in the LV. Consequently, LV EDP,
LA pressure, and pulmonary capillary wedge pressure
(PCWP) increase, and the PVL becomes increasingly
narrow (decreased native LV SV) and taller (increased
afterload pressure), and shifts rightward and upward
along the EDPVR. Because the EDPVR is nonlinear,
large increases in LV EDP may cause only subtle
increases in LV EDV. An echocardiogram showing a
persistently closed aortic valve during ECMO would
also signify a state of maximal LV loading and high
PCWP. These increases in LV pre-load and PCWP are
detrimental to blood oxygen saturation coming from
the lung and markedly increase myocardial oxygen
demand (increased PVA), which can worsen LV
function, especially in the setting of acute myocardial
ischemia or infarction.
These responses to ECMO can be modulated by
secondary regulatory factors that inﬂuence either
TPR or LV contractility. TPR can be reduced naturally
by the baroreceptors, pharmacologically (e.g., nitro-
prusside), or mechanically (e.g., by intra-aortic
balloon pumping). As illustrated in Figure 4B, a 50%
reduction in TPR during ECMO markedly blunts the
rise in LV EDP.
Short-term improvements in LV function can also
modulate the rise in PCWP. LV function can be
improved during ECMO due to increased central aortic
pressure, the improved coronary perfusion, normali-
zation of blood oxygen content (improved oxygen
delivery to the myocardium), and normalization of
CENTRAL ILLUSTRATION Mechanical Circulatory Support: 4 Options to Pump Blood Within the Cardiovascular System
Burkhoff, D. et al. J Am Coll Cardiol. 2015; 66(23):2663–74.
Although all forms of mechanical circulatory support return blood to the arterial system, they differ with respect to the site from which they draw blood. These dif-
ferences underlie differences in their hemodynamic effects. Percutaneous (A) and durable ventricular devices (B) that take blood from the LV have similar physiology.
Extracorporeal membrane oxygenation (ECMO) withdraws blood from the right atrium or venous system and utilizes a blood gas exchange unit (C). Percutaneous
devices can also achieve LA sourcing of blood (without need for a gas exchange unit) (D). LA ¼ left atrium/atrial; LV ¼ left ventricle/ventricular.
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2668acid-base and other metabolic abnormalities. Phar-
macological enhancement of contractility (e.g., by
b-agonists or phosphodiesterase inhibitors) is also
possible, butmaynot be beneﬁcial in cardiogenic shockdue to their independent effects to increase MVO2 and
potential effects on heart rate and arrhythmias. As
illustrated in Figure 4B, a 50% increase in LV Ees during
ECMO also blunts the primary rise in LV EDP.
FIGURE 4 Ventricular Effects of ECMO
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(A) Impact of extracorporeal membrane oxygenation (ECMO) on
pressure–volume loops, showing ﬂow-dependent increases of
end-diastolic pressures (EDPs), increases of effective arterial
elastance, and decreases in LV stroke volume. ECMO-dependent
increases in EDP can be partially mitigated by decreases in TPR
(B), and/or improvements in Ees (C). CGS ¼ cardiogenic shock;
RA-Ao ¼ right atrium to aorta; other abbreviations as in Figure 1.
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2669When secondary factors are insufﬁcient to self-
mitigate a rise in LV EDP, other strategies can be
utilized to reduce possible increases in afterload
pressure and allow for LV decompression. Theseinclude atrial septostomy (to allow left-to-right
shunting), a surgically placed LV vent, an intraaortic
balloon pump, or use of a percutaneous LV-to-aorta
ventricular-assist device (described in later text) (1,18).
Incorporation of a gas exchange unit that normal-
izes blood gases is a key feature of ECMO, compared
with other forms of MCS. It is important to note that
blood gases measured near the site of blood return do
not necessarily reﬂect blood gases throughout the
body. If, for example, blood is returned to the femoral
or iliac artery and pulmonary edema compromises
native lung function, oxygen delivery to the lower
extremities may be normal, although oxygen delivery
to the head and upper extremities may be signiﬁ-
cantly compromised.
In summary, hemodynamic responses to ECMO are
complex and variable among patients due to a host of
clinical factors. In some patients, it becomes readily
apparent that afterload reduction or mechanical LV
unloading is required, either when pulmonary edema
appears on a chest x-ray or PCWP is noted to be
elevated. Variable secondary effects of ECMO on TPR
and LV contractility can explain the variability of
responses among patients. However, even in the
presence of relatively large secondary effects, ECMO
by itself may not lead to signiﬁcant LV unloading.
LA-TO-ARTERIAL CIRCULATORY SUPPORT. Tempo-
rary LA-to-arterial MCS can be achieved with
extracorporeal devices, such as TandemHeart (Car-
diacAssist, Pittsburgh, Pennsylvania), which has a
ﬂow capacity up to w5 l/min. LA-to-arterial MCS has
also been investigated for long-term use in patients
with severe, but stable (INTERMACS $4) chronic
heart failure (19). The site of blood return is typically 1
or both femoral arteries for the percutaneous
approach, and the right subclavian or axillary artery
for the chronic application. Given that blood is
withdrawn directly from the LA, PCWP and LV EDP
decrease with this approach. In the case that the
patient has pulmonary edema, blood oxygenation can
be improved due to the reduction in PCWP. As for
ECMO, blood must exit the LV through the aortic
valve with LA-to-arterial MCS. Therefore, if arterial
pressure is increased during MCS, LV pressure gen-
eration must also increase. In contrast to ECMO, the
necessary increase in LV pressure generation can be
achieved by an isolated increase in end-systolic
volume (Figure 5A). Thus, PVA and MVO2 can be
unchanged or decreased by this approach.
These primary effects are modiﬁed when secondary
factors result in decreases in TPR and increases of
Ees. In such cases, end-systolic and end-diastolic
volumes can both decrease, along with PVA and
FIGURE 5 Ventricular Effects of LA-to-Arterial MCS
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(A) Flow-dependent changes in pressure–volume loops with left
atrial-to-aortic (LA-Ao) pumping, showing reducing end-diastolic
pressures, increasing end-systolic volume, and decreasing LV
stroke volume. (B) Effects on end-diastolic and end-systolic
volumes and pressure are modiﬁed by changes in TPR and Ees.
MCS ¼ mechanical circulatory support; other abbreviations as in
Figures 1 and 4.
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signiﬁcantly between patients, the net impact of LA-
to-arterial MCS, like ECMO, can vary between patients.
LV-TO-AORTA CIRCULATORY SUPPORT. Several
devices pump blood from the LV to the arterial sys-
tem, including percutaneous catheter-based trans-
valvular devices for temporary use and fully
implantable, durable, LV assist devices (LVADs),
intended for long-term or permanent support.
Percutaneous transvalvular devices include the
commercially available Impella 2.5, Impella CP,
Impella 5.0, and Impella LD family of devices
(Abiomed, Danvers, Massachusetts) and the Percuta-
neous Heart Pump (PHP, Thoratec, Pleasanton,
California, which has received CE Mark and is under
clinical investigation in the United States). Thesedevices can, in principle, reach mean ﬂows of
w5 l/min. Durable devices include the HeartMate II
(St. Jude Medical, St. Paul, Minnesota) and the HVAD
(HeartWare, Framingham Massachusetts), and a
number of other devices currently under clinical
evaluation (e.g., HeartMate III and MVAD). These
devices can reach mean ﬂows over 7 l/min. Although
these devices employ different mechanisms to pump
blood (e.g., axial, centrifugal, and mixed-ﬂow pump
technologies), are implanted with different tech-
niques, and have different ﬂow capacities, the same
principles govern their hemodynamic effects.
Continuous pumping of blood directly from the LV,
independent of the phase of the cardiac cycle, results
in loss of the normal isovolumic periods. This trans-
forms the PVL from its normal trapezoidal shape to a
triangular shape (Figure 6). Unlike the other forms of
support, removal of blood from the LV is not depen-
dent on ejection through the aortic valve. As pump
ﬂow rate increases, the LV becomes increasingly
unloaded (progressive leftward shifted PVL), peak LV
pressure generation decreases, and there are marked
decreases in PVA and MVO2. At the same time, arterial
pressure increases, such that peak LV pressure and
arterial pressure are increasingly dissociated
(Figure 6B to 6E). This direct unloading also results in
decreased LA and wedge pressures. As illustrated in
the cases described earlier, improved blood oxygen-
ation, systemic pressures, and perfusion may
improve the metabolic milieu and invoke beneﬁcial
secondary changes in LV contractility and TPR. For
the case of LV-to-arterial pumping, these secondary
changes result in even greater degrees of LV unload-
ing (Figure 7). Also note that for this particular case of
increased LV Ees and decreased TPR, LV pressure is
sufﬁcient to overcome aortic pressure, and LV ejec-
tion occurs; nevertheless, the more triangular shape
of the PVL is still present.
Another consideration for durable LV-to-arterial
MCS is the difference in characteristics between
axial and centrifugal ﬂow pumps, typiﬁed by the
HVAD and HeartMate II, respectively, the 2 pumps in
most common use today. Some authors argue that the
differences are signiﬁcant, largely on the basis of
theoretical considerations (14). However, in a recent
study in experimental heart failure in which these
types of pumps were compared (20), the authors
concluded that there were no pronounced acute
differences. This is consistent with our own recent
clinical data showing no signiﬁcant differences in
overall hemodynamic effects of these 2 pumps (7).
Further work on this topic is needed because new
pumps of both types are currently being introduced
into the clinic.
FIGURE 6 Ventricular Effects of LV-to-Arterial MCS
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(A) Flow-dependent changes of the pressure-volume loop with LV-to-aortic pumping. The loop becomes triangular and shifts progressively leftward (indicating
increasing degrees of LV unloading). Corresponding LV and aortic pressure waveforms at baseline (B), 4.5 l/min (C), 6.0 l/min (D) and 7.5 l/min (E). With increased ﬂow,
there are greater degrees of LV unloading and uncoupling between aortic and peak LV pressure generation. LVAD ¼ left ventricular assist device; other abbreviations as
in Figures 1, 4, and 5.
FIGURE 7 Secondary Increases in Ees and Decreases in TPR
Enhance Unloading Effects of LV-to-Aortic Pumping
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2671RIGHT HEART CATHETERIZATION
Descriptions in the preceding sections focused on
theoretical characterizations of primary and sec-
ondary effects of different forms of acute and
chronic MCS through the window of the pressure–
volume diagram. Because measurements of contin-
uous volume signals are mainly restricted to the
clinical research setting, direct application in everyday
clinical practice is not feasible. Nevertheless, these
theories help to inform which data to collect and
how to interpret it, not only on a general population
basis, but also potentially on a patient-by-patient
basis (17).
In this regard, information from standard PAC is
central for evaluating patients potentially in need of
MCS, for the deﬁnitive assessment of patient volume
status, adequacy of ventricular support, and for
diagnosis of potential MCS complications, including
pump thrombosis. A sound understanding of the
underlying theories reviewed earlier have helped
guide our own development of patient evaluation and
management strategies that aim to make maximal use
of PAC-derived measures.As a ﬁrst step towards that end, the theories and
simulations described earlier led us to propose a
means of evaluating the adequacy of MCS and medi-
cal therapy by simultaneous evaluation of central
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2672venous pressure (CVP), PCWP, and cardiac index over
a range of device speeds (7). To achieve this, patients
undergo a standardized speed ramp test in which
device rotations per minute (RPM) are initially
decreased to the lowest recommended value and are
then increased stepwise by a standardized amount. At
each RPM, hemodynamic parameters are recorded
after steady-state conditions are re-established
(generally 2 to 5 min). Maximal RPM for the test is
determined either by the maximal recommended
speed for the device, or the occurrence of hyperten-
sion, suction events, or arrhythmias. CVP and PCWP
are plotted as a function of each other, and theFIGURE 8 Impact of Rotational Speed Variations of Durable LVADs
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(A) Original tracings of right atrial (RA), pulmonary artery (PA), and pulm
measured during a ramp test. Note normal respiratory variations. (B) Sim
speed of a ventricular assist device is increased. Five zones of this doma
index (CI) is $2.0 l/min/m2. (C) Data from 4 different patients showing v
Uriel et al. (7). BiVF ¼ biventricular failure; LHF ¼ left heart failure; LVA
RHF ¼ right heart failure; RPM ¼ rotations per minute.individual data points can be coded, depending on
the adequacy of cardiac index (e.g., cardiac index
>2.0 l/min/m2). Figure 8A shows examples of original
tracings of RA, PA, and PCWP tracings obtained at the
highest and lowest speeds of a typical durable-LVAD
patient (7). As shown, the increase in RPM is associ-
ated with signiﬁcant decreases in PA pressures and
PCWP; RA pressure is inﬂuenced signiﬁcantly less.
Note normal respiratory variations; it is important for
proper results that readings be made at end-expiration
which, during spontaneous respiration, is during the
phase at which pressures are highest (note that auto-
mated computer analyses of these tracings generallyon Standard PAC-Derived Hemodynamics
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ultaneous changes in central venous pressure (CVP) and PCWP as
in are detailed in the text. Symbols further code for whether cardiac
ariability of responses to speed changes. B and C were modiﬁed from
D ¼ left ventricular assist device; PAC ¼ pulmonary artery catheter;
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2673do not account for the phase of respiration and can
provide misleading results). As illustrated in
Figure 8B, the CVP-PCWP diagram can be divided into
5 zones on the basis of proposed (though arbitrary)
clinically acceptable ranges of CVP (3 to 12 mmHg) and
PCWP (8 to 18 mmHg): 1) normal; 2) right heart failure;
3) left heart failure; 4) biventricular failure and/or ﬂuid
overload; and 5) hypovolemic zones. The test shown
consisted of 8 different RPMs (steps 0 to 7). This
particular patient starts with high values of CVP and
PCWP. As RPMs are increased, the CVP-PCWP point
moves into the normal range, including achievement
of an adequate cardiac index. Although pump speed
adjustments on the basis of ramp test results have not
yet been correlated with improved clinical outcomes,
it is suggested that the optimal speed can be deter-
mined by identifying the speed that provides normal
values for CVP, PCWP, and cardiac index. In this
example, the speed at steps 4 and 5 would satisfy this
condition.
An individual patient’s response depends on many
factors, such as volume status, intrinsic RV contrac-
tility, systemic and pulmonary vascular properties,
and any coexisting valvular lesions. Thus, not every
patient can be brought into the normal ranges for all
measured values. Such deviations suggest the need for
additional evaluations for deﬁnitive diagnosis and
medical therapies. CVP-PCWP relations measured
during ramp tests from 4 clinically stable, seemingly
well-compensated patients, 47 to 74 years of age who
were supported with a durable LVAD are shown in
Figure 8C (with cardiac index coded by symbol). These
patients had reasonably controlled blood pressures
(70 to 95 mm Hg, as assessed by Doppler opening
pressure) and devices showed no evidence device
thrombosis or malfunction (e.g., lactate dehydroge-
nase values 190 to 385 U/l). One patient (red) starts in
the “left heart failure” zone at low speed and moves
to the normal zone with increased speed. Another
patient (blue) remains with low CVP and PCWP ranges
independent of speed, suggesting a hypovolemic
state that might beneﬁt from volume administration
and/or reduction of diuretic therapy. A third patient
(cyan) remains with elevated CVP and PCWP despite
increases in speed, always with adequate cardiac
index, suggesting a ﬂuid overload state that would,
perhaps, beneﬁt from more diuresis. A fourth patient
(green) remains with elevated CVP with minor effects
on PCWP, suggestive of right-sided dysfunction.
Although applied here to patients with durable
devices, the same principles should apply to patients
receiving short-term percutaneous MCS.
The approach outlined in the preceding text illus-
trates that development of innovative approachesthat capitalize on standard hemodynamic measures
founded on advanced hemodynamic theories have
the potential to help in the management of MCS
patients. Whether this approach results in improved
outcomes, compared with current guidelines for
patient management by the International Society for
Heart and Lung Transplant (21), is the topic of
ongoing research. A preliminary retrospective study
suggests that use of invasive hemodynamic-guided
optimization of RPMs and medical therapy has the
potential to improve clinical outcomes (22). As pre-
viously demonstrated, more direct application of
hemodynamics can assist directly in device selection
and patient management.
SUMMARY
There is an increasing number of MCS options for
treating patients with acute and chronic hemody-
namic compromise. The characteristics of these
devices vary signiﬁcantly, and underlie signiﬁcant
differences in their primary hemodynamic effects and
secondary responses. Clinical data to guide optimal
device selection and use are currently lacking. Novel
approaches utilizing standard hemodynamic mea-
sures have the potential to be impactful. However,
the more fundamental principles of cardiac me-
chanics, ventricular–vascular coupling, and ventric-
ular–vascular-device coupling reviewed herein
provide an even broader foundation for clarifying the
issues and generating testable hypotheses to improve
clinical outcomes. Application of these principles is in
its infancy, but already yielding encouraging results
(7). Basic principles that we identiﬁed for each mode
of MCS have been illustrated using a cardiovascular
simulation with a set of parameters that is represen-
tative of patients undergoing MCS. However, patients
present with a vast range of combinations of cardiac,
vascular, and metabolic characteristics; each patient
may be considered unique. Understanding the fun-
damentals of ventricular-vascular-device interactions
as summarized herein and elsewhere (8,15) provides a
foundation for understanding individual patient re-
sponses. In this regard, it is noteworthy that there is
even less understanding of the physiology of MCS
solutions for profound biventricular failure, including
total artiﬁcial hearts, biventricular percutaneous de-
vices, or biventricular durable devices. The concepts
reviewed also provide the foundation for addressing
those complex settings.
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